Seeger Weiss Blog
Seeger Weiss Blog: Legal News and Analysis

Category : Osteoporosis

FDA Panels Recommend Clearer Fosamax Labels

September 19th, 2011

Fosamax, the subject of an ongoing Seeger Weiss investigation, is one of the four brands of bisphosphonates discussed in two advisory panels to the FDA on September 9. Bisphosphonates, drugs prescribed to women at risk of osteoporosis, have in recent years been demonstrated to cause fractures to the femur. Examining the mounting evidence, including the testimony of 18 victims who suffered atypical femoral fractures after taking the medication, the panels voted to recommend more specific instructions for how long Fosamax and other bisphosphonates should be used.

New York Times Article

Learn More about our Fosamax Investigation